Current Headlines

  1. Kelun-Biotech Receives IND Approval For SKB103, A Novel TAA-PD-L1 Bispecific ADC 3/24/2026

    Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) today announced that the Investigational New Drug (IND) application for SKB103, its self-developed novel bispecific antibody-drug conjugate with combined Tumor-Associated Antigen-targeting and Immuno-Oncology mechanisms (TAA-PD-L1 bsADC), has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the treatment of advanced solid tumors.

  2. Quotient Therapeutics Announces Collaboration With Merck To Discover Novel Drug Targets In Inflammatory Bowel Disease Using Somatic Genomics Platform Technology 3/24/2026

    Quotient Therapeutics, a company pioneering somatic genomics to inform breakthrough medicines, today announced that it has entered a multi-year research collaboration agreement with Merck, known as MSD outside the US and Canada, to discover novel drug targets in inflammatory bowel disease (IBD) using Quotient’s somatic genomics platform technology.

  3. Sinopia Biosciences Awarded NCI Grant To Advance LEADS Drug Discovery Platform For Oncology 3/24/2026

    Sinopia Biosciences, Inc., a biotechnology company advancing novel therapeutics identified using its proprietary LEADS (LEarn And DiScover) drug discovery platform, today announced it has been awarded a research grant from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to expand the application of its metabolomics-driven discovery capabilities to oncology.

  4. EndoCyclic Therapeutics Announces FDA Clearance Of Investigational New Drug (IND) Application For ENDO-205, A First-In-Class Non-Hormonal Precision Peptide Therapeutic For Endometriosis 3/23/2026

    EndoCyclic Therapeutics, a biopharmaceutical company developing precision peptide therapeutics and diagnostics for complex diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for its lead program, ENDO-205, a first-in-class, non-hormonal targeted peptide therapeutic for endometriosis.

  5. Ionis Announces Zilganersen New Drug Application For Alexander Disease (AxD) Accepted By FDA For Priority Review 3/23/2026

    Ionis Pharmaceuticals, Inc. oday announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for zilganersen, an investigational RNA-targeted medicine for Alexander disease (AxD), a rare, progressive and often fatal neurological condition.

  6. IntraBio Announces Submission Of Supplemental New Drug Application For Levacetylleucine For Ataxia-Telangiectasia 3/20/2026

    IntraBio Inc. today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for levacetylleucine for the treatment of Ataxia-Telangiectasia (A-T), a rare, progressive, inherited neurodegenerative disorder.

  7. Alloy Therapeutics Enters Into Agreement To Advance Novel Antibody Discovery Platform 3/17/2026

    Alloy Therapeutics, Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced an agreement with AbbVie to develop a new antibody platform to discover potent, specific, and effective antibodies against targets that are difficult to address with current technologies.

  8. ADDF Launches New Phase Of $150M Diagnostics Accelerator Initiative To Power Next Generation Of Alzheimer's Precision Medicine Worldwide 3/17/2026

    The Alzheimer's Drug Discovery Foundation (ADDF) today announced the launch of the third phase of its Diagnostics Accelerator (DxA), backed by an additional $50 million in funding, bringing the initiative's total to $150 million.

  9. Scientists Find Promising Drug Target For Tuberculosis 3/17/2026

    Researchers from Imperial and the London School of Hygiene & Tropical Medicine (LSHTM) have discovered a drug target that could potentially help tackle drug-resistant tuberculosis, one of the biggest causes of death worldwide.

  10. Dalriada Drug Discovery And Topos Bio Announce Collaboration To Advance Drug Discovery For Intrinsically Disordered Proteins 3/17/2026

    Dalriada Drug Discovery ("Dalriada"), a partnered discovery organization supporting small-molecule programs from hit identification through lead optimization, and Topos Bio ("Topos"), an AI-native biotechnology company developing therapeutics for intrinsically disordered proteins (IDPs), today announced a research collaboration to accelerate experimental validation for IDP drug discovery using advanced protein mass spectrometry and proteomics.